• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Biomea Fusion, Inc. - Common Stock (NQ: BMEA )

    4.230 +0.150 (+3.68%)
    Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Biomea Fusion, Inc. - Common Stock

    < Previous 1 2 3 Next >
    Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes
    From Biomea Fusion, Inc.
    Via GlobeNewswire
    Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D)
    Tuesday, December 17, 2024 at 8:00 am EST 
    From Biomea Fusion, Inc.
    Via GlobeNewswire
    Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
    From Biomea Fusion, Inc.
    Via GlobeNewswire
    Biomea Fusion Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia
    From Biomea Fusion, Inc.
    Via GlobeNewswire
    Biomea Fusion to Host Conference Call to Present initial Clinical Data from Phase I COVALENT-103 Study of BMF-500, a Covalent FLT3 Inhibitor, in Relapsed or Refractory Acute Leukemia
    From Biomea Fusion, Inc.
    Via GlobeNewswire
    Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
    From Biomea Fusion, Inc.
    Via GlobeNewswire
    Late-Breaker Oral Presentation Showing New Analysis from the Escalation Portion of COVALENT-111 Presented at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024)
    From Biomea Fusion, Inc.
    Via GlobeNewswire
    Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
    From Biomea Fusion, Inc.
    Via GlobeNewswire
    Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist Candidate
    From Biomea Fusion, Inc.
    Via GlobeNewswire
    Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate Highlights
    From Biomea Fusion, Inc.
    Via GlobeNewswire
    Biomea Fusion Announces Approval of “icovamenib” as International Nonproprietary Name for BMF-219
    Icovamenib is an oral covalent menin inhibitor in clinical development to investigate its impact on the function of insulin-producing beta cells 
    From Biomea Fusion, Inc.
    Via GlobeNewswire
    Biomea Fusion to Host Conference Call and Webcast on Wednesday, October 30th at 4:30 pm ET to Announce Our Lead Clinical Candidate, BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist and Preclinical Data Combining BMF-219 with a GLP-1
    From Biomea Fusion, Inc.
    Via GlobeNewswire
    Biomea Fusion to Present at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024)
    From Biomea Fusion, Inc.
    Via GlobeNewswire
    Biomea Announces Formation of Global Scientific Advisory Board with 22 World-Renowned Diabetes Experts
    International diabetes pioneers and thought leaders from 11 countries will work with Biomea leadership to unlock the potential of menin science and beta cell biology to advance BMF-219 and Biomea’s... 
    From Biomea Fusion, Inc.
    Via GlobeNewswire
    FDA Lifts Clinical Hold on BMF-219 in Type 2 and Type 1 Diabetes Trials
    From Biomea Fusion, Inc.
    Via GlobeNewswire
    Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
    From Biomea Fusion, Inc.
    Via GlobeNewswire
    Biomea Fusion Reports Second Quarter 2024 Financial Results and Corporate Highlights
    From Biomea Fusion, Inc.
    Via GlobeNewswire
    ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Biomea Fusion, Inc. Investors to Inquire About Securities Class Action Investigation – BMEA
    From The Rosen Law Firm PA
    Via GlobeNewswire
    ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Biomea Fusion, Inc. Investors to Inquire About Securities Class Action Investigation – BMEA
    From The Rosen Law Firm PA
    Via GlobeNewswire
    Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies
    EQNX::TICKER_START (NYSE:ATNM),(NASDAQ:SNDX),(NASDAQ:KURA),(NASDAQ:BMEA),(NYSE:JNJ) EQNX::TICKER_END 
    Via FinancialNewsMedia
    BMEA ANNOUNCEMENT: If You Have Suffered Losses in Biomea Fusion, Inc. (NASDAQ: BMEA), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
    From The Rosen Law Firm PA
    Via GlobeNewswire
    Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies
    From FN Media Group LLC
    Via GlobeNewswire
    Biomea Fusion, Inc. (BMEA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
    From Bronstein, Gewirtz & Grossman, LLC
    Via Business Wire
    Rosen Law Firm Encourages Biomea Fusion, Inc. Investors With Losses in Excess of $100K to Inquire About Securities Class Action Investigation – BMEA
    From The Rosen Law Firm, P.A.
    Via Business Wire
    INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Biomea Fusion, Inc. and Encourages Investors with Losses to Contact the Firm
    From Schall Law
    Via GlobeNewswire
    Biomea Fusion Announces BMF-219 in Diabetes Placed on Clinical Hold
    From Biomea Fusion, Inc.
    Via GlobeNewswire
    Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
    From Biomea Fusion, Inc.
    Via GlobeNewswire
    Biomea Fusion Announces Completion of Enrollment of First 3 Arms in Phase 2 Expansion Cohorts of COVALENT-111 Study for BMF-219 in Type 2 Diabetes
    BMF-219 is an investigational novel covalent menin inhibitor developed to regenerate insulin-producing beta cells 
    From Biomea Fusion, Inc.
    Via GlobeNewswire
    Biomea Fusion Reports First Quarter 2024 Financial Results and Corporate Highlights
    From Biomea Fusion, Inc.
    Via GlobeNewswire
    Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
    From Biomea Fusion, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.